Immunoassay MarketSize, Share & Industry Analysis, 2026-2034By ProductBy SpecimenBy TechnologyBy ApplicationBy End-use

Immunoassays are laboratory and point-of-care tests that detect and measure a target antigen or antibody using labeled reagents, typically run on automated analyzers or as single-use cartridges and kits. The category spans reagents, instruments and increasingly software that connects a laboratory's device fleet, taking forms ranging from bench-top chemiluminescence analyzers in hospital laboratories to lateral-flow rapid tests used at the point of care. Buyers include hospital and reference laboratories, blood banks, pharmaceutical and biotech companies running clinical trial assays, and academic research centers.

The global immunoassay market stood at USD 33.5 billion in 2025. A forecast-period rate of 6.82% takes it to USD 60.95 billion by 2034, and the study reports every year in between, passing USD 22.8 billion in 2020, USD 31 billion in 2024, USD 35.95 billion in 2026 and USD 47.25 billion in 2030.

On the product axis, growth rates run from 5.23% for ELISA Reagents & Kits up to 9.2% for Software & Services. ELISA Reagents & Kits carries the volume: USD 8.04 billion and 24% of revenue in 2025, USD 12.8 billion and 21% in 2034. Rapid Test Reagents & Kits, ELISPOT Reagents & Kits, Closed Ended Systems and Software & Services take share over the period; Reagents & Kits, ELISA Reagents & Kits, Western Blot Reagents & Kits, Other Reagents & Kits and Open Ended Systems give it up while still growing in absolute terms.

The specimen split puts Blood first, at USD 22.78 billion and 68% of revenue in 2025, rising to USD 39.62 billion and 65% in 2034. Saliva grows faster at 10.35% against 6.34%, moving from 9% of revenue to 12% by 2034. It cuts the same total as the product axis from a different commercial angle, so revenue does not add across the two.

USD 12.08 billion of 2025 revenue is generated in North America, 36.1% of the global total and the largest regional share; it reaches USD 20.42 billion by 2034. Europe is next at 26.1% and USD 8.75 billion, and Middle East and Africa last at 5.9%. Because Asia Pacific and Latin America take share, the revenue added by 2034 concentrates rather than spreading across all five regions.

Behind these figures sit five regions, nine product lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is triangulated from published sources and category proxies rather than an independently sourced count, and the same applies to the segment, regional and country breakdowns drawn from it.

• Revenue grows from USD 33.5 billion in 2025 to USD 60.95 billion in 2034, a compound annual rate of 6.82%, having reached USD 31 billion in 2024 from USD 22.8 billion in 2020.
• ELISA Reagents & Kits is the largest product line at USD 8.04 billion in 2025, a 24% share, reaching USD 12.8 billion and 21% of revenue by 2034.
• Fastest growth on the product axis belongs to Software & Services: 9.2% a year, USD 3.02 billion to USD 6.71 billion, and a share moving from 9% to 11%.
• Against a base case of USD 60.95 billion in 2034, the study also reports a bear case at USD 57.29 billion and a bull case at USD 64.61 billion, with the assumptions behind each set out separately.
• 36.1% of 2025 revenue is generated in North America, worth USD 12.08 billion and rising to USD 20.42 billion by 2034; Middle East and Africa is smallest at 5.9%.
• 86.09% of North America's base-year revenue comes from the United States alone: USD 10.4 billion in 2025, rising to USD 17.55 billion by 2034, which is why it is that region's worked example.
• Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region rather than a single blended series.

Three movements define the forecast period in the global immunoassay market: how the product mix changes, where regional weight shifts, and the rate at which the total compounds.

None of them reverses the market's direction. Every line and every region grows in absolute terms across the period; what changes is which of them captures the revenue added.

Software & Services outpaces ELISA Reagents & Kits. 9.2% against 5.23%: that gap, between Software & Services and ELISA Reagents & Kits, is the largest on the product axis. Over the forecast period that moves Software & Services from 9% of revenue to 11%, and ELISA Reagents & Kits from 24% to 21%. Neither contracts: USD 3.02 billion becomes USD 6.71 billion, USD 8.04 billion becomes USD 12.8 billion. What the spread decides is which of them a supplier's revenue is exposed to.

Growth concentrates in Asia Pacific and Latin America. Asia Pacific moves from 25.3% of revenue in 2025 to 29.5% in 2034, worth USD 8.48 billion rising to USD 17.98 billion; Latin America moves from 6.6% of revenue in 2025 to 6.8% in 2034, worth USD 2.21 billion rising to USD 4.15 billion. The offsetting side is North America at 36.1% moving to 33.5%, Europe at 26.1% moving to 24.5%, Middle East and Africa at 5.9% moving to 5.7%, none of which contracts. The practical consequence is that regional weighting decides whether a participant matches the market rate or trails it, regardless of how its own revenue reads.

The series never breaks trajectory. Year by year the total runs USD 22.8 billion in 2020, USD 31 billion in 2024, USD 33.5 billion in 2025, USD 35.95 billion in 2026, USD 47.25 billion in 2030 and USD 60.95 billion in 2034. The forecast rate of 6.82% sits against 8% over the historical period, so the projection extends an observed trend instead of proposing a new one. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the product and regional axes, not by the headline rate.

Software & Services adds the most incremental growth

The 6.82% forecast rate rests on three things that can be measured separately: the size of the existing base, the mix shift on the product axis, and where regional growth is concentrated.

Downside case: USD 57.29 billion rather than USD 60.95 billion by 2034

Upside case: USD 64.61 billion by 2034

Revenue is concentrated in ELISA Reagents & Kits

North America holds 36.1% of the global immunoassay market in 2025, worth USD 12.08 billion rising to USD 20.42 billion in 2034. By revenue it sits first across the study, and the ranking does not change between 2025 and 2034.

Share settles at 33.5% in 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

Segment composition follows the global pattern: ELISA Reagents & Kits largest at 24% of 2025 revenue, Software & Services fastest at 9.2%. North America is reported axis by axis and country by country in the full study.

USD 10.4 billion of North America's 2025 revenue is generated in the United States, the region's largest market, reaching USD 17.55 billion by 2034. Carrying 86.09% of the region in the base year, it sets North America's direction rather than contributing to it. Against regional totals of USD 12.08 billion in 2025 and USD 20.42 billion in 2034, it is the country the full report breaks out in detail.

The product pattern in the United States is the global one: 24% of 2025 revenue in ELISA Reagents & Kits, 21% by 2034, against 9.2% growth in Software & Services taking it from 9% to 11%. Since 86.09% of North America's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. Revenue by product for the United States is reported separately in the full report.

In the United States, immunoassay products are regulated as in vitro diagnostic devices under the Federal Food, Drug, and Cosmetic Act, placing them under the oversight of the Food and Drug Administration. Depending on the risk classification assigned to a given assay, a manufacturer must pursue either premarket notification or premarket approval before the product can be marketed, alongside adherence to the Quality System Regulation governing manufacturing controls. Clinical laboratories that run these assays are separately subject to Clinical Laboratory Improvement Amendments oversight, which sets requirements for laboratory certification and testing complexity categorization. Labelling must clearly state intended use, performance characteristics, and handling instructions to support accurate clinical interpretation by end users.

Siemens Healthineers, bioMérieux SA, Abbott Laboratories, Danaher Corporation (Beckman Coulter), Quidel Corporation, Ortho Clinical Diagnostics, Sysmex Corporation, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc., DiaSorin S.p.A., Tosoh Corporation, PerkinElmer, Inc. and Randox Laboratories Ltd are the suppliers covered in the United States. The commercially relevant division is 24% of 2025 revenue in ELISA Reagents & Kits, where the volume is, against 9.2% growth in Software & Services, where share moves. Country-level positioning and shares for each of these companies are part of the full report rather than this summary.

Canada is sized at USD 1.3 billion in 2025, rising to USD 2.15 billion by 2034; 3.88% of global revenue and 10.76% of North America. It is reported separately from the United States across every segmentation axis in the full report.

26.1% of the global immunoassay market sits in Europe in 2025, worth USD 8.75 billion rising to USD 14.93 billion in 2034. That makes it the second-largest region covered, in 2025 and again in 2034.

Share settles at 24.5% in 2034, a shift in share rather than in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

The product mix reported at global level applies here, with ELISA Reagents & Kits the largest line at 24% of 2025 revenue and Software & Services the fastest-growing at 9.2%. Europe is reported axis by axis and country by country in the full study.

Germany is the largest market within Europe, generating USD 2.35 billion in 2025 and projected to reach USD 3.85 billion by 2034. Its 26.86% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Regional revenue of USD 8.75 billion in 2025 and USD 14.93 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

The product pattern in Germany is the global one: 24% of 2025 revenue in ELISA Reagents & Kits, 21% by 2034, against 9.2% growth in Software & Services taking it from 9% to 11%. Its 26.86% weight in Europe means those movements carry straight into the regional totals. The full report reports Germany by product separately.

In Germany, immunoassay diagnostics fall under the European Union's In Vitro Diagnostic Regulation, which is enforced domestically through the Federal Institute for Drugs and Medical Devices. Manufacturers must classify their assays according to risk-based rules set out in the regulation, with higher-risk categories requiring conformity assessment by a notified body before a CE mark can be affixed. Suppliers must maintain a quality management system aligned with recognized international standards, compile technical documentation demonstrating performance and safety, and register devices and economic operators within the European database on medical devices. Labelling and instructions for use must be provided in German and include unique device identification.

The suppliers tracked in this study (Siemens Healthineers, bioMérieux SA, Abbott Laboratories, Danaher Corporation (Beckman Coulter), Quidel Corporation, Ortho Clinical Diagnostics, Sysmex Corporation, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc., DiaSorin S.p.A., Tosoh Corporation, PerkinElmer, Inc. and Randox Laboratories Ltd) compete in Germany across the product lines above. ELISA Reagents & Kits, at 24% of 2025 revenue, is where the volume sits, and Software & Services, growing at 9.2%, is where position changes hands over the forecast period.

The United Kingdom is sized at USD 1.85 billion in 2025, rising to USD 3.05 billion by 2034; 5.52% of global revenue and 21.14% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

Within Europe, France accounts for 16% of regional revenue and 4.18% of the global total, worth USD 1.4 billion in 2025 and USD 2.3 billion by 2034.

In Asia Pacific, 25.3% of global revenue puts 2025 at USD 8.48 billion on the way to USD 17.98 billion by 2034. It is a leading region on this axis, third by revenue throughout the period.

29.5% of global revenue sits here by 2034, up from the 2025 level, on growth above the market's own 6.82%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

Within the region the product split tracks the global one; 24% of 2025 revenue in ELISA Reagents & Kits, fastest growth of 9.2% in Software & Services. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.

China is the largest market within Asia Pacific, generating USD 3.1 billion in 2025 and projected to reach USD 7.05 billion by 2034. 36.56% of the region in the base year makes it the largest market here without making it the region. The region itself runs USD 8.48 billion to USD 17.98 billion over the same period, and this is the market carrying the country-level detail in the full report.

China buys along the same lines as the market globally; ELISA Reagents & Kits first at 24% of 2025 revenue and 21% in 2034, Software & Services fastest at 9.2% on a share moving from 9% to 11%. Its 36.56% weight in Asia Pacific means those movements carry straight into the regional totals. The full report reports China by product separately.

In China, immunoassay reagents and instruments are regulated as in vitro diagnostic devices by the National Medical Products Administration. Products are classified according to risk, with lower-risk assays subject to a filing procedure and higher-risk assays requiring formal registration supported by clinical evaluation data generated domestically or accepted from recognized overseas trials. Manufacturers must operate under a quality management system consistent with national good manufacturing practice requirements and secure a registration certificate before commercial distribution. Imported products additionally require designation of a local agent responsible for regulatory liaison and post-market surveillance. Labelling, instructions for use, and packaging must be presented in Chinese and specify intended use and storage conditions.

Siemens Healthineers, bioMérieux SA, Abbott Laboratories, Danaher Corporation (Beckman Coulter), Quidel Corporation, Ortho Clinical Diagnostics, Sysmex Corporation, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc., DiaSorin S.p.A., Tosoh Corporation, PerkinElmer, Inc. and Randox Laboratories Ltd are the suppliers covered in China. ELISA Reagents & Kits, at 24% of 2025 revenue, is where the volume sits, and Software & Services, growing at 9.2%, is where position changes hands over the forecast period.

6.27% of global revenue is generated in Japan; USD 2.1 billion in 2025, reaching USD 3.55 billion in 2034, and 24.76% of Asia Pacific.

Within Asia Pacific, India accounts for 12.38% of regional revenue and 3.13% of the global total, worth USD 1.05 billion in 2025 and USD 2.55 billion by 2034.

USD 2.21 billion of 2025 revenue is generated in Latin America, 6.6% of the global immunoassay market rising to USD 4.15 billion in 2034. Among the five regions it ranks fourth by revenue in both years.

Share climbs to 6.8% by 2034, because it outgrows the market's 6.82%; the revenue added here is disproportionate to where the region started.

Segment composition follows the global pattern: ELISA Reagents & Kits largest at 24% of 2025 revenue, Software & Services fastest at 9.2%. Revenue for Latin America is broken out by every segmentation axis and by country in the full report.

USD 1.05 billion of Latin America's 2025 revenue is generated in Brazil, the region's largest market, reaching USD 1.92 billion by 2034. Its 47.51% of base-year regional revenue leads the region, though enough sits elsewhere that Latin America is not a proxy for it. Set against USD 2.21 billion and USD 4.15 billion for the region, it is why this market rather than a smaller one is the one reported in full.

The product pattern in Brazil is the global one: 24% of 2025 revenue in ELISA Reagents & Kits, 21% by 2034, against 9.2% growth in Software & Services taking it from 9% to 11%. With 47.51% of Latin America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Brazil carries its own product breakdown in the full report.

In Brazil, immunoassay devices are regulated by the National Health Surveillance Agency, known locally as ANVISA, which oversees in vitro diagnostic products under its medical device framework. Manufacturers and importers must obtain product registration or, for lower-risk categories, complete a simplified notification, with the applicable route determined by the assay's risk classification. Facilities are expected to demonstrate compliance with Good Manufacturing Practice requirements, verified through inspection for higher-risk categories. Technical dossiers must document analytical performance, intended use, and safety data. Labelling, package inserts, and instructions for use must be presented in Portuguese, and products must remain traceable throughout distribution to support post-market vigilance obligations.

The suppliers tracked in this study (Siemens Healthineers, bioMérieux SA, Abbott Laboratories, Danaher Corporation (Beckman Coulter), Quidel Corporation, Ortho Clinical Diagnostics, Sysmex Corporation, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc., DiaSorin S.p.A., Tosoh Corporation, PerkinElmer, Inc. and Randox Laboratories Ltd) compete in Brazil across the product lines above. ELISA Reagents & Kits, at 24% of 2025 revenue, is where the volume sits, and Software & Services, growing at 9.2%, is where position changes hands over the forecast period.

Within Latin America, Mexico accounts for 28.05% of regional revenue and 1.85% of the global total, worth USD 0.62 billion in 2025 and USD 1.18 billion by 2034.

USD 1.97 billion of 2025 revenue is generated in Middle East and Africa, 5.9% of the global immunoassay market with USD 3.47 billion projected for 2034. Among the five regions it ranks fifth by revenue in both years.

Its share moves to 5.7% by 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

ELISA Reagents & Kits leads here as it does globally, at 24% of 2025 revenue, and Software & Services again grows fastest at 9.2%. Middle East and Africa is reported axis by axis and country by country in the full study.

29.44% of Middle East and Africa's base-year revenue comes from Saudi Arabia; USD 0.58 billion, rising to USD 1.02 billion by 2034. At 29.44% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Against regional totals of USD 1.97 billion in 2025 and USD 3.47 billion in 2034, it is the country the full report breaks out in detail.

The product pattern in Saudi Arabia is the global one: 24% of 2025 revenue in ELISA Reagents & Kits, 21% by 2034, against 9.2% growth in Software & Services taking it from 9% to 11%. Because the country carries 29.44% of Middle East and Africa, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. The full report reports Saudi Arabia by product separately.

In Saudi Arabia, immunoassay products are regulated by the Saudi Food and Drug Authority under its medical device framework, which governs in vitro diagnostics through the national Medical Devices Interim Regulation. Manufacturers and local authorized representatives must register devices through the Saudi Authorization system before marketing, with the classification and depth of technical review determined by the assay's risk category. Conformity to recognized international quality and safety standards is expected, along with maintenance of a quality management system and post-market surveillance capability. Labelling and instructions for use must be provided in Arabic alongside English, clearly identifying intended use, handling requirements, and the responsible local representative.

In Saudi Arabia the field is Siemens Healthineers, bioMérieux SA, Abbott Laboratories, Danaher Corporation (Beckman Coulter), Quidel Corporation, Ortho Clinical Diagnostics, Sysmex Corporation, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc., DiaSorin S.p.A., Tosoh Corporation, PerkinElmer, Inc. and Randox Laboratories Ltd. The commercially relevant division is 24% of 2025 revenue in ELISA Reagents & Kits, where the volume is, against 9.2% growth in Software & Services, where share moves.

Within Middle East and Africa, South Africa accounts for 20.3% of regional revenue and 1.19% of the global total, worth USD 0.4 billion in 2025 and USD 0.68 billion by 2034.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by product, specimen, technology, application, end-use, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.